Core Insights - Profusa, Inc. is set to present a Late Breaking Clinical Trial Update on its Lumee™ Oxygen tissue monitoring platform at the Paris Vascular Insights (PVI) 2025 conference, highlighting its innovative technology for continuous monitoring of tissue oxygen in patients with peripheral artery disease [1][2] - The Lumee technology allows for real-time measurement of tissue oxygen levels directly within the body, representing a significant advancement in biochemistry monitoring for both clinical and home use [2][3] - Profusa aims to provide personalized biochemical data through its long-lasting, injectable biosensors, which are designed to deliver actionable medical-grade information for both personal and medical applications [3] Presentation Details - The presentation titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)" will be delivered by Dr. Peter Schneider on December 13, 2025, at 1pm CET [2] - The event will take place at the Carrousel du Louvre in Paris, France, showcasing the latest innovations in vascular and endovascular surgery [2] Company Overview - Profusa is based in Berkeley, California, and is recognized for its pioneering work in developing tissue-integrated sensors that continuously transmit reliable biochemical data [3] - The company is led by a team of experienced professionals and aims to create a new generation of affordable biosensors that enhance patient care through personalized data [3]

Core Insights - Sharecare has won 22 Digital Health Awards in the Fall 2025 competition, recognizing its contributions to improving care quality and outcomes in the healthcare ecosystem [1][2][3] Awards and Recognition - Sharecare received five Gold awards, particularly for its health navigation platform and Diabetes Prevention Program in the disease management category [2] - The company also earned 17 additional awards across Silver, Bronze, and Merit levels for its patient education and health literacy initiatives, including interactive tools and digital therapeutics [3][4] Commitment to Quality - Sharecare adheres to NCQA guidelines, demonstrating its commitment to high performance and continuous improvement [4] - The company is one of only three in the U.S. to hold three-year NCQA Accreditations in Case Management, Population Health, and Wellness and Health Promotion simultaneously [4] Company Overview - Sharecare is a digital healthcare company that provides software and tech-enabled services aimed at improving care quality and lowering costs [5] - The company utilizes data-driven AI insights and evidence-based resources to help stakeholders manage healthcare effectively [5]

Core Insights - Profusa, Inc. has successfully reduced its net debt from $34 million to $14 million as of October 31, 2025, following a merger with NorthView Acquisition Corporation [2][9] - The company aims to achieve potential revenues of $200 to $250 million by 2030, with near-term revenue targets of $0.5 to $2 million for 2026 and $9 to $13 million for 2027 [4] Business Highlights - The merger with NorthView Acquisition Corporation was completed, resulting in a company equity value of $155 million [8] - Manufacturing capabilities have been built out, with plans to begin product shipments and generate revenue in early 2026 [8] - Profusa has expanded its sales footprint in Europe, currently covering approximately 35% of the European population for its Lumee™ Oxygen tissue monitoring platform [8] - The company has entered into several clinical and commercial collaborations with prominent vascular surgeons [8] Financial Highlights - Profusa raised $12 million in gross proceeds from a convertible PIPE note, with $10 million remaining available [9] - An additional $7 million was raised through an Equity Line of Credit (ELOC) as of October 31, 2025, with $93 million still available [9] - Cash and cash equivalents increased to $4 million, and net debt was reduced to $14 million as of October 31, 2025, down from $48 million last quarter [9]

Repurchase of the Catheter Convertible Notes removes conversion overhang and supports QHSLab’s financial discipline and growth outlook. Company Reports Robust Q3 2025 Year-Over-Year Revenue Growth, Expanded Gross Profit, and Strengthened Operating Metrics West Palm Beach, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a medical device and digital health company enabling primary care physicians to deliver reimbursable, value-based chronic-disease and preventive-care services ...

Group 1 - Tempus AI, Inc. is recognized as one of the top digital health stocks to invest in, with positive sentiment from Wall Street following its Q3 results [1] - The company's Q3 performance was driven by a significant increase in oncology test volumes by approximately 27% and a surge in hereditary testing, leading to total genomics revenue of around $253 million and overall sales of $334 million [2] - Management has raised its full-year guidance due to the durability of growth levers, despite GAAP results remaining negative due to stock compensation and other costs [2][3] Group 2 - Canaccord Genuity maintained a Buy rating on Tempus AI but slightly reduced its price target from $110 to $95, citing the potential for AI deployment in clinical practice to drive long-term revenue growth [1] - The company's gross profit reached approximately $210 million, and adjusted EBITDA turned positive, indicating improved financial health [2] - Tempus AI applies artificial intelligence to clinical and molecular data, focusing on personalizing treatment, particularly in oncology, and aims to expand its technology across various diseases [3]

Doximity, Inc. (NYSE:DOCS) is one of the best digital health stocks to buy now. On November 3, 2025, Morgan Stanley maintained its Equal-Weight rating on Doximity and held its price target steady at $62. The firm’s analyst Craig Hettenbach cited third-quarter checks indicating stronger-than-expected growth, driven in large part by the company’s video module business. The note suggested that adoption momentum in this segment may be outperforming earlier expectations. In addition, the analyst addressed con ...

Hinge Health, Inc. (NYSE:HNGE) is one of the best digital health stocks to buy now. On November 5, 2025, Piper Sandler nudged its Hinge Health, Inc. (NYSE:HNGE) target to $71 (Overweight) after a Q3 that ran hotter than the models. Revenue landed at $154.2 million, up 53% year over year and roughly $12 million above consensus (FactSet/Street was about $142–$142.5 million). Piper said the beat was powered by yield improvements, and that upside flowed through at a 93.4% incremental margin to adjusted operat ...

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $6 million for the third quarter, which includes a non-cash loss of $4.4 million due to changes in the fair value of equity investments [23][24] - Non-GAAP loss for the quarter was $446,000, primarily reflecting incremental contractor development costs for the Veris implantable device [24][25] - Cash burn rate for the third quarter was $900,000, which included approximately $500,000 in outside contractor development costs for Veris [20][24] Business Line Data and Key Metrics Changes - Lucid's revenue for the quarter was $1.2 million, with test volume exceeding 2,800, consistent with the target range of 2,500-3,000 tests [10][11] - Veris launched the commercial phase of its strategic partnership with OSU, targeting 1,000 patients in the first year for enrollment in a registry [12][14] Market Data and Key Metrics Changes - The Medicare contractor meeting in September was successful, with experts endorsing Medicare coverage for EsoGuard, marking a significant milestone for Lucid [10][11] - PAVmed remains the largest shareholder of Lucid, owning approximately 23% of the common shares outstanding, although it no longer has voting control [21] Company Strategy and Development Direction - The company aims to stabilize its corporate structure and balance sheet, with plans to operate as a diversified commercial life sciences company with multiple independently financed subsidiaries [5][6] - PAVmed is pursuing additional technologies, including a partnership with Duke University for an endoscopic imaging technology for esophageal precancer [8][46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's positioning to capitalize on Lucid's market opportunities and the potential for Medicare coverage [9][10] - The company is focused on expanding its commercial offerings and enhancing its value proposition through clinical support services and AI-based clinical decision tools [17][43] Other Important Information - The company has restructured its debt, exchanging about 80% of its outstanding debt for new Series C preferred equity [19] - The development of the Veris implantable device is progressing well, with a clear regulatory pathway established for FDA submission [34][38] Q&A Session Summary Question: Status of the implantable monitor development - Management confirmed that the development work has relaunched with a new manufacturing partner and that the clinical requirements for FDA submission are modest [33][34] Question: Timing for commercialization conversations with other cancer centers - Management indicated that they plan to start expanding commercial activities to other centers in the first quarter after gaining experience with OSU [40][41] Question: Exclusivity and timing of the endoscopic imaging technology agreement - Management stated that a definitive license agreement is expected soon, and the technology will be developed within a separate subsidiary of PAVmed [45][46]

Core Insights - DarioHealth Corp. is transitioning to a high-margin recurring revenue model, which has led to improved financials despite a decline in revenue during this transition [2][10][19] - The company has signed 45 new clients in 2025, exceeding its goal of 40, and is targeting $12.4 million in new business [5][6] - DarioHealth's commercial pipeline for 2026 stands at $69 million, indicating strong momentum and potential for revenue acceleration [2][5] Financial Performance - Revenue for Q3 2025 was $5.0 million, down from $7.4 million in Q3 2024 and $5.4 million in Q2 2025 [10][17] - Gross profit for Q3 2025 was $3.0 million, with a gross margin of 60%, up from 52% in Q3 2024 [11][20] - Operating expenses decreased by $17.2 million, or 31%, in the first nine months of 2025 compared to the same period in 2024 [9][22] Client and Market Expansion - DarioHealth's diversified customer base includes over 125 clients, with more than 50% of new contracts being multi-condition offerings [2][7] - The company is focusing on larger clients, which has nearly doubled the average employer customer size [6][7] - Strategic collaborations, such as with OneStep for fall-risk assessment, are expected to enhance ROI for health plans [6] Cash Position and Future Outlook - As of September 30, 2025, DarioHealth had $31.9 million in cash and cash equivalents, following a $17.5 million oversubscribed private placement [9][12] - The company anticipates reaching cash flow breakeven by late 2026 to early 2027 [9][12] - Continued reductions in operating expenses and a robust commercial pipeline are expected to support future growth [9][12]

Core Insights - DarioHealth Corp. presented research at ISPOR Europe 2025 demonstrating significant medical cost reductions associated with its digital health platform, particularly among high-risk populations [1][2][3] - The study provides real-world evidence linking behavior change facilitated by Dario's platform to measurable economic impacts, marking a critical milestone for the company [1][3] - Dario's platform integrates connected devices, AI-driven insights, and human coaching to improve health outcomes and reduce overall medical expenditures [1][2] Company Overview - DarioHealth Corp. is a leading digital health company focused on managing chronic conditions through a user-centric digital therapeutics platform [2][3] - The platform offers personalized interventions driven by data analytics and one-on-one coaching for conditions such as diabetes, hypertension, and behavioral health [2][3] Market Impact - Chronic diseases are a major contributor to the $4.9 trillion annual healthcare costs in the U.S., highlighting the importance of Dario's solutions in addressing these challenges [1] - Dario's platform is currently utilized by employers, health plans, and partners across the U.S. to support members with various chronic health needs [1][2]